期刊
IMMUNOTHERAPY
卷 11, 期 5, 页码 407-428出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2018-0193
关键词
immunotherapy; nonsquamous; NSCLC; PD-L1 inhibitor; pembrolizumab
类别
资金
- Merck Co., Inc.
Aim: A systematic review and network meta-analysis were conducted to evaluate the efficacy of pembrolizumab+pemetrexed+platinum relative to other regimens in metastatic nonsquamous non-small-cell lung cancer (NSq-NSCLC). Patients & methods: Eligible studies evaluated first-line regimens in NSq-NSCLC patients without known targetable mutations. Relative treatment effects were synthesized with random effects proportional hazards Bayesian network meta-analyses. Results: The hazard ratio (HR) for overall survival (OS) for pembrolizumab+pemetrexed+platinum was statistically significant over all platinum-doublet (HR range: 0.42-0.61), platinum-doublet+bevacizumab (HR range: 0.44-0.53) and platinum-doublet+atezolizumab regimens (HR range: 0.56-0.62). Additionally, pembrolizumab+pemetrexed+platinum numerically improved OS over atezolizumab+paclitaxel+carboplatin+bevacizumab (HR: 0.65; 95% credible interval: 0.43, 1.01). Pembrolizumab+pemetrexed+platinum had 95.6% probability of being the best treatment regimen for OS. Conclusion: Pembrolizumab+pemetrexed+platinum is likely the most efficacious first-line regimen for metastatic NSq-NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据